528
Participants
Start Date
September 15, 2018
Primary Completion Date
January 6, 2022
Study Completion Date
April 27, 2022
CF101 2mg
CF101 tablets, 2mg BID for 16 weeks
CF101 3mg
CF101 tablets, 3mg BID for 16 weeks
Apremilast 30mg
Apremilast tablets, 30mg BID for 16 weeks
Placebo Oral Tablet
Placebo tablets, BID for 16 weeks
Clinical Centre of Republika Srpska, Banja Luka
University Clinical Centre Mostar, Mostar
Clinical Centre of Sarajevo University, Sarajevo
"Multiprofile Hospital for Active Treatment - Pazardzhik", Pazardzhik
"MHATRahila AngelovaAD, Department of Skin and Venereal Diseases", Pernik
"University Multiprofile Hospital for Active Treatment - D-r Georgi Stranski - EAD, Pleven, Clinic of Skin and Venereal Diseases", Pleven
"Diagnostic-Consultative Aleksandrovska EOOD", Sofia
"Diagnostic-Consultative Centre XX - Sofia EOOD", Sofia
"Ambulatory for Specialized Medical Help - Group Practice Dermatology - Clinic EuroDerma OOD", Sofia
K. Papp Clinical Research, Waterloo
Clinical Hospital Center Rijeka, Rijeka
Sestre milosrdnice University Hospital Center, Zagreb
Rambam Medical Center, Haifa
Institutul de Cardiologie, Chisinau
"Spitalul Clinic Municipal Nr. 3 Sfanta Treime", Chisinau
Spitalul Clinic Republican, Chisinau
Centrum Usług Medycznych MaxMed, Bochnia
Gdańskim Centrum Zdrowia, Gdansk
All-MED Centrum Medyczne, Lodz
Miejski Szpital Zespolony Klinika Dermatologii Chorób Przenoszonych Drogą Płciową i Immunologii klinicznej, Olsztyn
Lubelskie Centrum Diagnostyczne, Świdnik
ETG Zamość, ul. Szczebrzeska 11i, Zamość
Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL, Brasov
SC PELICAN Impex SRL, Oradea
Spitalul Clinic Județean de Urgență Sibiu, Sibiu
Clinical Centre of Serbia, Belgrade
Clinical Centre Nis, Niš
Military Hospital Nis, Niš
General Hospital Sremska Mitrovica, Sremska Mitrovica
General Hospital Zajecar, Zaječar
Lead Sponsor
Can-Fite BioPharma
INDUSTRY